x min read

Advanced Medical Isotope Corp (OTCMKTS:ADMD) Explodes Up The Charts

Advanced Medical Isotope Corp (OTCMKTS:ADMD) Explodes Up The Charts
Written by
Alex Carlson
Published on
April 7, 2016
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

Advanced Medial Isotope Corp (OTCMKTS:ADMD) has quickly emerged as a volume leader and microcap runner on the OTC markets. This comes from the company getting favorable coverage from the investment newsletter the Wealthy Biotech Trader. On March 18, the Wealthy Biotech Trader called ADMD "the biotech company about to turn the 120-year-old cancer radiation industry on its head." The newsletter said:

The Wealthy Biotech Trader (or "WBT"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a new stock pick, Advanced Medical Isotope (ADMD), which WBT believes has the ability to cause a massive paradigm shift in the cancer treatment space, and potentially capture a large segment of the burgeoning internal radiation therapy market. We look to follow this company as they expect to make another FDA submission later this year, which should catapult the stock if they receive the anticipated marketing clearance.

In small print at the bottom of the article, the newsletter disclosed that it is receiving $50k per month from ADMD along with 100k restricted preferred shares. The newsletter also said that "will convert these shares into common shares sell them into the market as soon as the statutory 144 hold period has lapsed."ADMD describes itself as "a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the company will evaluate its alternatives before finalizing its plans."The latest news from the company is that its IsoPet Solutions division will focus on bringing ADMD's yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers. Consider that there are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions' goal is to establish the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. ADMD expects the initial treatments to be coordinated through the Chair of the Company's Veterinary Medicine Advisory Board, Dr. Alice Villalobos.The latest report from the Wealthy Biotech Trader did not discuss ADMD's IsoPet Solutions division. Instead, the newsletter said:

"While the company prepares to file for FDA submission, its share price is currently less than a penny. If FDA clearance is given, there is little doubt that the prospects for the company's patented Y-90 products are very bright. It won't be surprising to see the company's shares surge again by more than 2,000%."

The problem here is that ADMD failed to obtain marketing clearance for their Y-90 RadioGel Device from the FDA already twice. The company did say in November that it was going to try again, but we remain skeptical it will get approval on its third attempt.Currently trading with a market cap of $11.59 million, ADMD has exploded up the charts on a lot of hype from the Wealthy Biotech Trader. At the end of September 2015, ADMD filed that it had $7396 in cash, $42,149 in current assets, $12,054 in revenues, and $8.8 million in liabilities. We urge our readers and subscribers to trade ADMD actively and don't be left holding the bag. We will be updating Insider Financial as soon as we know more. For continuing coverage on ADMD, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in ADMD and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.